Prasinezumab
Based on 1 Customer Validation
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : ≥99.0%
- CAS 番号: 1960462-19-4
- 分子量:145.26 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
α-synuclein アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
|
α-synuclein Aggregation |
体外実験
Prasinezumab against an epitope in the carboxyl terminus of human α-synuclein. Prasinezumab binds to human aggregated α-synuclein with a high affinity and avidity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized SNCA Protein, Human (HY-P70577) can bind Prasinezumab. The EC50 for this effect is 11.77 ng/mL. -
Flow cytometric analysis of 1X106 Hela cells with Prasinezumab (HY-P99405, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 1960462-19-4
-
性状 Liquid
-
分子量 145.26 kDa
-
Color Colorless to light yellow
-
SMILES
[Prasinezumab]
-
別名
PRX 002; RG 7935; RO 7046015
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
純度とドキュメンテーション
-
データシート (256 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)